Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Drug: SA53-OS (phase 2)Drug: SA53-OS (phase 1)
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Lamassu Bio Inc
- Target Recruit Count
- 70
- Registration Number
- NCT06578624
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
News
No news found